利伐沙班在非瓣膜性房颤治疗中的研究进展

The latest progress of Rivaroxaban in the treatment of nonvalvular atrial fibrillation

房颤是最常见的心律失常之一,作为独立的危险因素,其导致卒中及体循环栓塞事件,常常危及患者的生命。事实证明,抗凝治疗是预防和减少房颤所致卒中的有效手段,且多项指南指出建议CHA2DS2-VASC评分≥2分的患者应用抗凝剂。利伐沙班是一种新型的抗凝药,和华法林不同,其直接作用于凝血因子Xa,遏制凝血级联反应,为近年来房颤治疗研究的热点。

Atrial fibrillation is one of the most common arrhythmias. It is an independent risk factor which leads to stroke and systemic embolism events,often endangering the lives of patients. Anticoagulant therapy has been proved to be an effective means of preventing and reducing stroke caused by atrial fibrillation,and several guidelines suggest that patients with a CHA2 DS2-VASC score over or equal to 2 should be given anticoagulant therapy. Rivaroxaban is a new anticoagulant,as opposed to Warfarin,it acts directly on coagulation factor Xa to inhibit coagulation cascade reaction,which is a hot topic in the treatment of atrial fibrillation in recent years.